Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Annals of Surgical Oncology Année : 2022

Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study

Abdelkader Taibi
Olivia Sgarbura
  • Fonction : Auteur
Martin Hübner
  • Fonction : Auteur
Sylvia M Bardet
Mohammed Alyami
  • Fonction : Auteur
Naoual Bakrin
  • Fonction : Auteur
Sylvaine Durand Fontanier
  • Fonction : Auteur
Clarisse Eveno
  • Fonction : Auteur
Johan Gagniere
  • Fonction : Auteur
Basile Pache
  • Fonction : Auteur
Marc Pocard
  • Fonction : Auteur
François Quenet
  • Fonction : Auteur
Hugo Teixeira Farinha
  • Fonction : Auteur
Emilie Thibaudeau
  • Fonction : Auteur
Frederic Dumont
  • Fonction : Auteur
Olivier Glehen
  • Fonction : Auteur

Résumé

Background This retrospective multicenter cohort study compared the feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) with or without intraoperative intravenous 5-fluorouracil (5-FU) and leucovorin (L). Methods Our study included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM) treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group). Results In total, 101 patients (263 procedures) were included in the PIPAC-Ox group and 30 patients (80 procedures) were included in the PIPAC-Ox + 5-FU/L group. Common Terminology Criteria for Adverse Events v4.0 grade 2 or higher adverse events occurred in 48 of 101 (47.5%) patients in the PIPAC-Ox group and in 13 of 30 (43.3%) patients in the PIPAC-Ox + 5-FU/L group (p = 0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p = 0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups. Conclusions The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.

Domaines

Cancer

Dates et versions

hal-04413348 , version 1 (23-01-2024)

Identifiants

Citer

Abdelkader Taibi, Olivia Sgarbura, Martin Hübner, Sylvia M Bardet, Mohammed Alyami, et al.. Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study. Annals of Surgical Oncology, 2022, 29 (8), pp.5243-5251. ⟨10.1245/s10434-022-11577-2⟩. ⟨hal-04413348⟩

Collections

UNILIM CNRS XLIM
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More